La Jolla seeks Chinese approval for active TB (tuberculosis) test:
This article was originally published in Clinica
La Jolla Diagnostics plans to submit its rapid test for active tuberculosis (TB) to the Chinese Ministry of Health in March for approval, following successful results from clinical trials at Beijing Children's Hospital. The product, which will be distributed by Hong Kong-based Winnimax, is the only test to rapidly determine whether the disease is in an active state, said the La Jolla, California-based company.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.